In early online publication in Nature, Harvard's Bill Hahn is senior author on work that used an RNAi screen to find synthetic lethal partners of oncogenic KRAS -- "gene products that, when inhibited, result in cell death only in the presence of an oncogenic allele." They found that the IkappaB kinase TBK1 was needed in cells with mutant KRAS, and by suppressing this gene they induced apoptosis in human cancer cells that depend on oncogenic KRAS expression.